Anika Therapeutics (ANIK) Net Margin (2010 - 2025)
Anika Therapeutics (ANIK) posted quarterly Net Margin of 4.93% for Q4 2025, up 5840.0% year-over-year from 0.08% in Q4 2024, and down 262.07% quarter-over-quarter from 3.04% in Q3 2025.
Anika Therapeutics (ANIK) Net Margin (2010 - 2025) Analysis & Trends
Anika Therapeutics (ANIK) has reported Net Margin for 16 consecutive years, with 4.93% the latest figure, recorded in Q4 2025.
- In Q4 2025, Net Margin rose 5840.0% year-over-year to 4.93%; the TTM figure through Jun 2026 stood at 0.55% (up 4108.0% YoY), while the FY2025 annual figure was 0.8%, up 3886.0% from the prior year.
- Net Margin eased to 4.93% in Q4 2025 per ANIK's latest filing, from 3.04% in the prior quarter.
- Across five years, Net Margin topped out at 17.12% in Q2 2021 and bottomed at 558.26% in Q4 2023.
- Historically, Net Margin has averaged 56.93% across 5 years, with a median of 7.55% in 2022.
- Annual changes were most pronounced in 2022 — Net Margin plunged 35229 bps — and 2024, when it soared 49494 bps.
- Anika Therapeutics' Net Margin stood at 9.03% in 2021, then tumbled by 3902 bps to 361.32% in 2022, then plunged by 55 bps to 558.26% in 2023, then surged by 89 bps to 63.33% in 2024, then soared by 92 bps to 4.93% in 2025.
- Business Quant data shows ANIK's Net Margin at 4.93% in Q4 2025, 3.04% in Q3 2025, and 2.4% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -13.91% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 9.28% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.51% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -3.16% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.06% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 3.95% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 10.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.93% |
| Sep 30, 2025 | 3.04% |
| Jun 30, 2025 | 2.40% |
| Mar 31, 2025 | -3.50% |
| Dec 31, 2024 | -63.33% |
| Sep 30, 2024 | -94.97% |
| Jun 30, 2024 | 7.98% |
| Mar 31, 2024 | -8.81% |
| Dec 31, 2023 | -558.26% |
| Sep 30, 2023 | -15.77% |
| Jun 30, 2023 | -6.19% |
| Mar 31, 2023 | -27.20% |
| Dec 31, 2022 | -361.32% |
| Sep 30, 2022 | -10.34% |
| Jun 30, 2022 | -7.17% |
| Mar 31, 2022 | -7.93% |
| Dec 31, 2021 | -9.03% |
| Sep 30, 2021 | 1.40% |
| Jun 30, 2021 | 17.12% |
| Mar 31, 2021 | 8.28% |